Il Nuovo Postiglione - AstraZeneca withdraws Covid vaccine as demand dives

NYSE - LSE

BCC	2.64%	79.21	$
CMSC	-0.53%	20.81	$
RIO	0.42%	103.27	$
CMSD	-0.34%	20.69	$
BTI	-1.12%	55.35	$
AZN	-1.27%	162.7	$
BCE	-0.59%	23.67	$
JRI	-0.58%	12.14	$
GSK	-1.96%	49.89	$
RBGPF	0%	70	$
NGG	-0.06%	78.12	$
BP	0.52%	43.81	$
RELX	-3.21%	35.51	$
RYCEF	0.7%	19.92	$
VOD	1.89%	16.9	$

AstraZeneca withdraws Covid vaccine as demand dives

ECONOMY 08.05.2024

AstraZeneca withdraws Covid vaccine as demand dives / Photo: Saeed KHAN - AFP/File

Anglo-Swedish drugmaker AstraZeneca on Wednesday said it was withdrawing Covid vaccine Vaxzevria, one of the first produced in the deadly pandemic, citing "commercial reasons" following a slump in demand.

Text size:

"As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied," an AstraZeneca spokesperson added in a statement.

"We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the Covid-19 pandemic."

AstraZeneca rapidly developed the successful Covid-19 jab during the coronavirus pandemic which erupted in the first half of 2020.

Vaxzevria, developed alongside Oxford University, was at first offered at cost but Astra decided in late 2021 to sell it for profit.

But the world pivoted towards mRNA vaccines, particularly the one produced by US drugs giant Pfizer and German peer BioNTech, after rare blood-clot problems with Astra's jab increased public hesitancy about taking it.

Sales collapsed further as global Covid restrictions were fully lifted worldwide and the world emerged from the global health crisis.

The AstraZeneca spokesperson said the group had begun the process from taking it off the market in the Europe, Middle East and Africa (EMA) region.

The company will work with other regulators globally to start market authorisation withdrawals for the Vaxzevria "where no future commercial demand for the vaccine is expected".

The spokesperson said that, according to independent estimates, "over 6.5 million lives were saved in the first year of use alone" and more than three billion doses were supplied globally.

"We are incredibly proud of the role Vaxzevria played in ending the global pandemic," the spokesperson said.

"Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic. "

C.Albano--INP

Featured

Bangladesh measles toll nears grim 1,000-child mark

Bangladesh's deadliest measles outbreak in decades is nearing the grim milestone of 1,000 child deaths, as a devastating epidemic sweeps through the country and crowded hospital wards fill with struggling babies.

Bolivia farmers return to streets over diesel price hikes

Several hundred coca farmers and supporters of former Bolivian president Evo Morales demonstrated in the central city of Cochabamba on Friday over the government's doubling of diesel prices, AFP reporters said.

S&P Revises Outlook on Freedom Holding Corp. and Core Subsidiaries to Positive

S&P Global Ratings has revised the outlook on the long-term credit ratings of Nasdaq-listed Freedom Holding Corp. and its four core operating subsidiaries from “stable” to “positive,” while affirming their international credit ratings.

Moody’s Assigns First-Time Insurance Financial Strength Ratings to Freedom Insurance and Freedom Life

Moody’s Ratings has assigned insurance financial strength ratings to two Freedom Holding Corp. (Nasdaq: FRHC) insurance subsidiaries for the first time. Freedom Finance Insurance JSC, operating as Freedom Insurance, received Ba1 local- and foreign-currency insurance financial strength ratings, while Freedom Life JSC received Baa3 ratings. Both carry stable outlooks.